Following this transaction James Hollingshead’s holding in the company was increased by 12.2% to a total of $9.42 million. Following James Hollingshead’s last RMD Buy transaction on November 27, 2018, the stock climbed by 6.2%.
Based on Resmed Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $588 million and quarterly net profit of $106 million. In comparison, last year the company earned revenue of $524 million and had a net profit of $86.13 million. RMD’s market cap is $15.93B and the company has a P/E ratio of 48.19. Currently, Resmed Inc has an average volume of 221.5K.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $94.50, reflecting a -15.6% downside.
In the last 30 days, insiders have sold $1.6M worth of RMD shares and purchased $544.3K worth of RMD shares. The insider sentiment on Resmed Inc has been negative according to 96 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
James Hollingshead’s trades have generated a 3.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.